Epicriptine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. Epicriptine is also known as beta-dihydroergocryptine presents a molecular formula of 9,10 alpha-dihydro-13'-epi-b-ergocryptine.
- Mechanism
- Curator reviewed · 1 reference
Epicriptine effect is mainly due to the agonistic activity on dopamine receptor. This activity is categorized as part of the ergoline class which is defined as a producer of a vasoconstrictive effect. Please refer to DB01049 and to know more about the isomer please refer to DB11274.
- Primary indication
- Please refer to DB01049 and to know more about the isomer please refer to DB11274.Curator reviewed · 1 structured indication
- Formula / weight
- C32H43N5O5 · 577.726 g/mol (avg)
- First approval
- United States, 1991
- Also known as
- dihydro-beta-ergocryptine · Epicryptine
- Code names
- Dcn 203-922
Resolves to
SBFXHXZNBNFPHV-PXXBSISHSA-NSMILES[H][C@@]12CCCN1C(=O)[C@]([H])([C@H](C)CC)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)CWhat you can answer from here — as of August 30, 2026
Which other approved drugs treat the same conditions as Epicriptine, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account